GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$61.64
-1.28 (-2.03%)
As of May 9, 1:21 AM ET ·
Financial Highlights (FY 2026)
Revenue
167.67M
Net Income
-465,219,634
Gross Margin
48.5%
Profit Margin
-277.5%
Rev Growth
+38.4%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 48.5% 48.5% 65.8% 65.8%
Operating Margin -382.0% -343.8% 9.2% 8.6%
Profit Margin -277.5% -263.6% 7.6% 7.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 167.67M 121.17M 2.02B 1.78B
Gross Profit 81.25M 58.72M 1.33B 1.17B
Operating Income -640,459,486 -416,574,067 184.76M 152.85M
Net Income -465,219,634 -302,592,809 154.03M 135.92M
Gross Margin 48.5% 48.5% 65.8% 65.8%
Operating Margin -382.0% -343.8% 9.2% 8.6%
Profit Margin -277.5% -263.6% 7.6% 7.7%
Rev Growth +38.4% +38.4% +15.5% +5.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.78B 1.62B
Total Equity 1.86B 2.14B
D/E Ratio 0.96 0.76
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -489,044,842 -335,761,075 214.07M 192.49M
Free Cash Flow 137.52M 156.47M